<DOC>
	<DOCNO>NCT00037206</DOCNO>
	<brief_summary>The combination Anidulafungin plus AmBisome® may offer improved outcome patient treat Invasive Aspergillosis ( IA ) . The purpose study determine safety clinical microbiological effectiveness anidulafungin plus AmBisome® treat patient locate United States , Europe , South Africa .</brief_summary>
	<brief_title>A Safety &amp; Effectiveness Study Intravenous Anidulafungin With AmBisome® Treatment Invasive Aspergillosis ( IA ) .</brief_title>
	<detailed_description />
	<mesh_term>Aspergillosis</mesh_term>
	<mesh_term>Anidulafungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<criteria>Diagnosis definite IA outside pulmonary system definite probable pulmonary IA Life expectancy : great 72 hour Pregnant female Hypersensitivity anidulafungin echinocandin therapy Hypersensitivity Tween 80 ( polysorbate 80 ) tartaric acid Hypersensitivity amphotericin B deoxycholate constituent AmBisome unless , opinion investigator , benefit therapy outweigh risk . Aspergillomain absence invasive disease Abnormal blood chemistry : Bilirubin &gt; 3 time upper limit normal ; AST ( aspartate aminotransferase ) ALT ( alanine aminotransferase ) &gt; 5 time upper limit normal Greater five day therapeutic dos systemic therapy current Aspergillusassociated condition cumulative dose 5 mg/Kg amphotericin , 25 mg/Kg lipid formulation amphotericin , 2g itraconazole current condition . Prophylactic use azoles amphotericin acceptable . Less 4 week since prior participation investigational drug device study , exception cytotoxic , antiretroviral agent therapy AIDSrelated opportunistic infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Invasive Aspergillosis</keyword>
</DOC>